{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:31:49Z","timestamp":1787808709117,"version":"build-2784847793"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaad.2017.01.060","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T23:40:38Z","timestamp":1685576438000},"page":"1326-1337.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Commonly prescribed medications associated with alopecia"],"prefix":"10.1016","volume":"88","author":[{"given":"Jessica","family":"Mounessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Caravaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Domozych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Dellavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory A.","family":"Dunnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.01.060_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12788\/j.sder.2015.0160","article-title":"Alopecia areata update","volume":"34","author":"Hordinsky","year":"2015","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2017.01.060_bib2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4065\/70.7.628","article-title":"Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2017.01.060_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clindermatol.2015.09.004","article-title":"Trichodystrophies: a hair-raising differential diagnosis","volume":"33","author":"Vij","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib4","first-page":"304370","article-title":"Prevalence of psychological disorders in patients with alopecia areata in comparison with normal subjects","volume":"2014","author":"Aghaei","year":"2014","journal-title":"ISRN Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00002018-199410040-00005","article-title":"Drug-induced hair loss and hair growth. Incidence, management and avoidance","volume":"10","author":"Tosi","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2017.01.060_bib6","first-page":"145","article-title":"Drug-induced alopecia: review of the literature","volume":"50","author":"Llau","year":"1995","journal-title":"Therapie"},{"key":"10.1016\/j.jaad.2017.01.060_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2230.2002.01080.x","article-title":"Telogen effluvium","volume":"27","author":"Harrison","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3949\/ccjm.76a.08080","article-title":"Diffuse hair loss: its triggers and management","volume":"76","author":"Harrison","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jaad.2017.01.060_bib9","first-page":"356","article-title":"Diagnosing and treating hair loss","volume":"80","author":"Mounsey","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaad.2017.01.060_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sder.2008.12.001","article-title":"Chemotherapy-induced alopecia","volume":"28","author":"Trueb","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2017.01.060_bib11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1176\/ajp.2006.163.8.1451","article-title":"Hair loss as a side effect of lamotrigine treatment","volume":"163","author":"Hillemacher","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaad.2017.01.060_bib12","unstructured":"Brown T. 100 best-selling, most prescribed branded drugs through March. In: Brown T, editor. Available at: http:\/\/www.medscape.com\/viewarticle\/844317. Accessed February 20, 2017."},{"key":"10.1016\/j.jaad.2017.01.060_bib13","unstructured":"RxList.com website. Top drugs - U.S. only. Top 200 names searched. Available at: http:\/\/www.rxlist.com\/script\/main\/hp.asp. Accessed February 20, 2017."},{"key":"10.1016\/j.jaad.2017.01.060_bib14","unstructured":"Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et\u00a0al. Oxford Centre for Evidence-based Medicine, levels of evidence 1998."},{"key":"10.1016\/j.jaad.2017.01.060_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/03009740902922612","article-title":"Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors","volume":"38","author":"Exarchou","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jaad.2014.03.005","article-title":"Alopecia areata\u00a0occurring during anti-TNF therapy: a national multicenter prospective study","volume":"70","author":"Tauber","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00044011-200323090-00008","article-title":"Reversibility of tacrolimus-induced alopecia : a case report and literature review","volume":"23","author":"Chan","year":"2003","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaad.2017.01.060_bib19","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V96.4.1618","article-title":"Alopecia and dalteparin: a previously unreported association","volume":"96","author":"Barnes","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.01.060_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11536190-000000000-00000","article-title":"Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database","volume":"33","author":"Tengstrand","year":"2010","journal-title":"Drug Safety"},{"key":"10.1016\/j.jaad.2017.01.060_bib21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1101\/gad.223172.113","article-title":"The incidental pore: CaV1.2 and stem cell activation in quiescent hair follicles","volume":"27","author":"Coulombe","year":"2013","journal-title":"Genes & Development"},{"key":"10.1016\/j.jaad.2017.01.060_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2133.2009.09043.x","article-title":"Irreversible and\u00a0severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer","volume":"160","author":"Prevezas","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/000155550410021466","article-title":"Telogen effluvium caused by magnesium valproate and lamotrigine","volume":"85","author":"Patrizi","year":"2005","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.jaad.2017.01.060_bib24","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/annonc\/mdh349","article-title":"A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer","volume":"15","author":"Tabernero","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib25","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1634\/theoncologist.2012-0332","article-title":"Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia","volume":"18","author":"Komen","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2017.01.060_bib27","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaad.2009.08.024","article-title":"Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"64","author":"Hepper","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib31","first-page":"465","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2017.01.060_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1523-1747.ep12371760","article-title":"Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles","volume":"102","author":"Philpott","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.det.2012.08.002","article-title":"Drugs and hair loss","volume":"31","author":"Patel","year":"2013","journal-title":"Dermatologic Clinics"},{"key":"10.1016\/j.jaad.2017.01.060_bib34","unstructured":"Gleevec (Imatinib Mesylate) Drug Information: Clinical Pharmacology Prescribing Information at RxList 2016."},{"key":"10.1016\/j.jaad.2017.01.060_bib35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/rheumatology\/keu145","article-title":"Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database","volume":"53","author":"Bene","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.jaad.2017.01.060_bib36","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases","volume":"74","author":"Faivre","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2012.02.007","article-title":"Multi-layered environmental regulation on the homeostasis of stem cells: the saga of hair growth and alopecia","volume":"66","author":"Chen","year":"2012","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2017.01.060_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cell.2015.02.016","article-title":"Organ-level quorum sensing directs regeneration in hair stem cell populations","volume":"161","author":"Chen","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2017.01.060_bib39","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jid.2016.04.014","article-title":"STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction","volume":"136","author":"Legrand","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00228-006-0102-6","article-title":"Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands","volume":"62","author":"de Vries","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2017.01.060_bib41","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","article-title":"Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial","volume":"16","author":"Musch","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.jaad.2017.01.060_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jir.1997.17.27","article-title":"Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C","volume":"17","author":"Castro","year":"1997","journal-title":"J\u00a0Interferon Cytokine Research"},{"key":"10.1016\/j.jaad.2017.01.060_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0305-7372(79)80039-0","article-title":"Interferon: an anti-cancer agent?","volume":"6","author":"Priestman","year":"1979","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaad.2017.01.060_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000247518","article-title":"Telogen effluvium due to recombinant interferon alpha-2b","volume":"184","author":"Tosti","year":"1992","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.jaad.2017.01.060_bib45","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/01.TP.0000061602.03327.E2","article-title":"Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation","volume":"75","author":"Meier-Kriesche","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2017.01.060_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1523-1755.2002.00424.x","article-title":"Post-transplant renal function in the first year predicts long-term kidney transplant survival","volume":"62","author":"Hariharan","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaad.2017.01.060_bib47","first-page":"384","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jaad.2017.01.060_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TP.0b013e31817442cf","article-title":"Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results","volume":"86","author":"Bolin","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2017.01.060_bib49","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.tp.0000181195.67084.94","article-title":"Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients","volume":"80","author":"Tricot","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2017.01.060_bib50","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/S0041-1345(99)00602-8","article-title":"Two cases of tacrolimus-induced alopecia following kidney transplantation","volume":"31","author":"Ushigome","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaad.2017.01.060_bib51","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1046\/j.0022-202x.2001.01570.x","article-title":"Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil","volume":"117","author":"Li","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0049-3848(01)00335-8","article-title":"Clinical experiences with low-molecular weight heparins in pediatric patients","volume":"103","author":"Hofmann","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaad.2017.01.060_bib53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2710.2006.00769.x","article-title":"Enoxaparin-induced alopecia in patients with cerebral venous thrombosis","volume":"31","author":"Wang","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jaad.2017.01.060_bib54","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1016\/S0272-6386(03)00211-7","article-title":"Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin","volume":"41","author":"Sarris","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaad.2017.01.060_bib55","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.V97.9.2914","article-title":"Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation","volume":"97","author":"Apsner","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.01.060_bib56","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/bjon.2014.23.Sup16.S4","article-title":"Scalp cooling: management option for chemotherapy-induced alopecia","volume":"23","author":"Roe","year":"2014","journal-title":"Br J Nurs (Mark Allen Publishing)"},{"key":"10.1016\/j.jaad.2017.01.060_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2133.2005.06608.x","article-title":"\u2018Atrophic telogen effluvium\u2019 from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans","volume":"153","author":"Bleiker","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib58","first-page":"681","article-title":"Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: a Case-Control Study of Adverse Events in a National Database","volume":"14","author":"Lai","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-977X(96)00384-7","article-title":"A calcium antagonistic effect of the new antiepileptic drug lamotrigine","volume":"7","author":"von Wegerer","year":"1997","journal-title":"European Neuropsychopharmacol"},{"key":"10.1016\/j.jaad.2017.01.060_bib60","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/annonc\/mds095","article-title":"Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients","volume":"23","author":"Kluger","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","article-title":"Permanent chemotherapy-induced alopecia: case report and review of the literature","volume":"63","author":"Tallon","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"38 Suppl 2","key":"10.1016\/j.jaad.2017.01.060_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0959-8049(01)00415-4","article-title":"Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials","author":"Twelves","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2017.01.060_bib63","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"Lilenbaum","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib64","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","article-title":"Alopecia in patients treated with molecularly targeted anticancer therapies","volume":"26","author":"Belum","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib65","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib66","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2230.2010.03852.x","article-title":"Folliculitis decalvans associated with erlotinib","volume":"35","author":"Hoekzema","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib67","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib68","doi-asserted-by":"crossref","first-page":"21277","DOI":"10.1016\/S0021-9258(19)36601-3","article-title":"Epidermal growth factor suppresses nitric oxide and hydrogen peroxide production by keratinocytes. Potential role for nitric oxide in the regulation of wound healing","volume":"267","author":"Heck","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2017.01.060_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","article-title":"Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages","volume":"83","author":"Nanney","year":"1984","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib70","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2017.01.060_bib71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1684\/ejd.2015.2684","article-title":"Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: a six-year follow up","volume":"26","author":"Dervis","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib73","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a\u00a0review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaad.2017.01.060_bib74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM200108233450814","article-title":"Cutaneous reactions to STI571","volume":"345","author":"Brouard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.01.060_bib75","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2003.04151_4.x","article-title":"A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec)","volume":"120","author":"Drummond","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2017.01.060_bib76","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.transci.2013.01.002","article-title":"Successful management of imatinib despite alopecia and nail necrosis","volume":"48","author":"Ergene","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jaad.2017.01.060_bib77","first-page":"1248","volume":"9","author":"Marcucci","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2017.01.060_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2006.03.012","article-title":"PDGF isoforms induce and maintain anagen phase of murine hair follicles","volume":"43","author":"Tomita","year":"2006","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2017.01.060_bib79","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib80","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase\u00a0III study of pegylated liposomal doxorubicin plus\u00a0bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.01.060_bib81","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.det.2007.01.005","article-title":"Drug reactions affecting hair: diagnosis","volume":"25","author":"Tosti","year":"2007","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2017.01.060_bib82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jdcr.2015.06.013","article-title":"Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline","volume":"1","author":"Chen","year":"2015","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.jaad.2017.01.060_bib83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F","article-title":"The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models","volume":"65","author":"Sredni","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaad.2017.01.060_bib84","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1088\/0031-9155\/50\/17\/010","article-title":"Modelling of temperature and perfusion during scalp cooling","volume":"50","author":"Janssen","year":"2005","journal-title":"Phys Med Biol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221730155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221730155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:23:06Z","timestamp":1759274586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221730155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S019096221730155X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.01.060","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commonly prescribed medications associated with alopecia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.01.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}